Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04378959
Other study ID # IRB00233514
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 1, 2021
Est. completion date June 2, 2023

Study information

Verified date August 2023
Source Johns Hopkins University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this randomized, double-blind, placebo-controlled crossover study, up to 84 patients with non-radicular neck pain will be allocated in a 1:1 ratio to receive up to 3 topical lidocaine or placebo patches, to be applied 12 hours per day. At the end of 4 weeks, patients will return for patients' post-phase I treatment evaluation. Patients will crossover to receive up to 3 identical-looking topical patches of the treatment patients did not receive, to be applied in the same fashion for the same 4-week period. The primary outcome measure will be average neck pain over the past week, 4 weeks post-treatment. A positive categorical outcome (i.e. responder) will be defined as a 2-point or greater decrease in average neck pain coupled with a patient global impression of change score >/= 5/7.


Description:

84 patients will be allocated to receive lidocaine patch or an identical placebo patch for phase I of this crossover study. Depending on the area of pain, up to 3 patches can be applied. Patches will be applied for 12 hours on and 12 hours off (e.g. from 8 PM to 8 AM or 8 AM to 8PM) depending on whether a person's pain is worse in the day or night. At the end of 4 weeks of treatment, patients will return to clinic for the post-phase I treatment evaluation, at which time outcome measures will be collected. Patients will then enter a 1-week washout period, after which patients will return between 1 and 3 weeks (depending on patients' availability) to receive the treatment patch patients did not receive in phase I (i.e. lidocaine for group II patients and placebo for group I patients). The short washout period is justifiable based on the short half-life of lidocaine (90-120 minutes) and is consistent with previous topical lidocaine crossover studies. The crossover patch will be applied in the same fashion as in the 1st phase, again for a 4-week duration. In order to reduce confounding variables, subjects in both groups must agree to not seek any additional pain management treatment as long as patients remain in the study. However, some treatments, such as physical therapy or exercise that are widely recommended can continue, so patients will be told to advise patients' pain clinic physician of any new treatments patients wish to seek during this time period. Subjects will be also be advised that patients can be prescribed rescue medications in the form of a non-steroidal anti-inflammatory drug or acetaminophen, or tramadol (up to 100 mg/d) for those who have already failed a non-steroidal anti-inflammatory drug and acetaminophen, or cannot take the drugs for medical reasons (e.g. renal disease, high cardiovascular risk). The primary outcome measure will be average neck pain over the past week, 4 weeks post-treatment. A positive categorical outcome (i.e. responder) will be defined as a 2-point or greater decrease in average neck pain coupled with a patient global impression of change score


Recruitment information / eligibility

Status Completed
Enrollment 76
Est. completion date June 2, 2023
Est. primary completion date June 2, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria: - Age 18 to 90 years - Tenderness to palpation over affected areas (using average 4 kg force for 70 kg person) - Average pain score >/= 4 over the week prior to enrollment - On stable doses of analgesics for 2 weeks prior to enrollment - Chronic mechanical neck pain > 3 months in duration - Boundaries are upper trapezius, mastoid processes, shoulders Exclusion Criteria: - Radicular pain as determined by clinical presentation - Opioid dose in oral morphine equivalents/day > 30 - Moderate or severe hepatic disease (will obtain blood work and exclude individuals with aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times the normal range. - Previous neck surgery - Known structural defect presumed to be the primary pain generator (e.g. severe degenerative disc or facet joint disease) - Serious medical (e.g. unstable angina) or psychiatric (e.g. poorly controlled depression, active substance abuse) that could interfere with treatment or pain response - Secondary gain - Pregnancy or breastfeeding - painDETECT score > 18 - Known allergy to lidocaine - Diffuse pain phenotype (e.g. fibromyalgia) - Cervical pain greater in area than 3 patches (10 x 14 cm/patch) - Skin defects (e.g. burns, active infection) in area(s) of application that could result in significant systemic absorption

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Lidocaine patch
Up to 3 patches will be applied for 12 hours on (e.g. from 8 AM to 8 PM for those whose pain is worse during the day, or from 8 PM to 8 AM for those whose pain is worse at night) and 12 hours off x 4 weeks.
Placebo patch
Up to 3 patches will be applied for 12 hours on (e.g. from 8 AM to 8 PM for those whose pain is worse during the day, or from 8 PM to 8 AM for those whose pain is worse at night) and 12 hours off x 4 weeks.

Locations

Country Name City State
United States Johns Hopkins Blaustein Pain Treatment Center Baltimore Maryland
United States DC VA Medical Center Washington District of Columbia

Sponsors (5)

Lead Sponsor Collaborator
Johns Hopkins University Pain Management Institute Bethesda-Washington-Maryland, Scilex Pharmaceuticals, Inc., Walter Reed National Military Medical Center, Washington D.C. Veterans Affairs Medical Center

Country where clinical trial is conducted

United States, 

References & Publications (5)

Cohen SP, Hooten WM. Advances in the diagnosis and management of neck pain. BMJ. 2017 Aug 14;358:j3221. doi: 10.1136/bmj.j3221. — View Citation

Hashmi JA, Baliki MN, Huang L, Parks EL, Chanda ML, Schnitzer T, Apkarian AV. Lidocaine patch (5%) is no more potent than placebo in treating chronic back pain when tested in a randomised double blind placebo controlled brain imaging study. Mol Pain. 2012 — View Citation

Hsieh LF, Hong CZ, Chern SH, Chen CC. Efficacy and side effects of diclofenac patch in treatment of patients with myofascial pain syndrome of the upper trapezius. J Pain Symptom Manage. 2010 Jan;39(1):116-25. doi: 10.1016/j.jpainsymman.2009.05.016. Epub 2 — View Citation

Lin YC, Kuan TS, Hsieh PC, Yen WJ, Chang WC, Chen SM. Therapeutic effects of lidocaine patch on myofascial pain syndrome of the upper trapezius: a randomized, double-blind, placebo-controlled study. Am J Phys Med Rehabil. 2012 Oct;91(10):871-82. doi: 10.1 — View Citation

Predel HG, Giannetti B, Pabst H, Schaefer A, Hug AM, Burnett I. Efficacy and safety of diclofenac diethylamine 1.16% gel in acute neck pain: a randomized, double-blind, placebo-controlled study. BMC Musculoskelet Disord. 2013 Aug 21;14:250. doi: 10.1186/1471-2474-14-250. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Mean reduction in average neck pain score on 0-10 numerical rating scale Mean reduction in average neck pain score over the past week at week 4 compared to baseline on 0-10 numerical rating scale (higher pain scores represent greater pain) 4 weeks
Secondary Average neck pain score on 0-10 numerical rating scale Average neck pain score over the past week on 0-10 numerical rating scale (higher pain scores represent greater pain) 4 weeks
Secondary Mean reduction in worst neck pain score on 0-10 numerical rating scale Mean reduction in worst neck pain score over the past week at week 4 compared to baseline on 0-10 numerical rating scale (higher pain scores represent greater pain) 4 weeks
Secondary Worst neck pain score on 0-10 numerical rating scale Worst neck pain score over the past week on 0-10 numerical rating scale (higher pain scores represent greater pain) 4 weeks
Secondary Neck disability index score Neck disability index score on 0 to 100 percent scale (higher scores represent greater disability) 4 weeks
Secondary Mean reduction in neck disability index score Mean reduction in neck disability index score over the past week at week 4 compared to baseline (higher scores represent greater disability) 4 weeks
Secondary Number of participants with a positive outcome Positive outcome is defined as a greater than or equal to 2-point decrease in average neck pain on 0-10 NRS scale coupled with a score of greater than or equal to 5 on a 7-point patient global impression of change scale. 4 weeks
Secondary Patient global impression of change (PGIC) score 1-7 scale evaluating, with higher scores indicating greater improvement. 4 weeks
Secondary Athens Insomnia Scale score Scale measuring sleep dysfunction on an 8-question 0-24 scale, with higher numbers indicating greater dysfunction. 4 weeks
Secondary Hospital Anxiety and Depression Scale score 14-question scale measuring anxiety and depression, with each question scored as 0-3 (higher numbers represent greater anxiety or depression). 4 weeks
Secondary Pain pressure threshold Pain pressure threshold, measured via algometry 3 times over the most tender area (mean of 3 measurements) 4 weeks
See also
  Status Clinical Trial Phase
Completed NCT05293847 - Postural Based Telerehabilitation in Mechanic Neck Pain N/A
Completed NCT04060004 - The Effects of Dry Needling on the Superficial Neck Musculature N/A
Recruiting NCT06204627 - TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain N/A
Active, not recruiting NCT05870371 - The Effect of the Feldenkrais Method on Pain and Function in Patients With Chronic Neck Pain N/A
Completed NCT06049316 - Scapular Stabilization vs Functional Exercises on Chronic Neck Pain N/A
Recruiting NCT05944354 - Wearable Spine Health System for Military Readiness
Completed NCT02904668 - Self-management Program in Chronic Neck Pain N/A
Completed NCT02731014 - Dry Needling for Patients With Neck Pain N/A
Completed NCT03147508 - Investigating Clinical Indicators of Spine Related Dysfunction Patterns. A Clinical Study on Neck Pain Patients.
Completed NCT02882061 - Examination of Cervical Thoracic Differentiation Testing in Individuals With Neck Pain N/A
Completed NCT02638987 - EMG Activity Before, During and After Dry Needling N/A
Active, not recruiting NCT02843269 - Multiple-component Workplace FRamed Intervention to Decrease Occupational Muscle Pain - FRIDOM N/A
Enrolling by invitation NCT02485795 - Observational Study of the Impact of Genetic Testing on Healthcare Decisions and Care in Interventional Pain Management N/A
Completed NCT02225873 - The Effectiveness of Exercises Protocol in Management of Neck Pain N/A
Completed NCT02245425 - Comparison of Two Thoracic Manipulation Techniques to Improve Neck Pain N/A
Completed NCT02235207 - Effectiveness of Fustra—Exercise Program in Neck and Low Back Pain N/A
Completed NCT02190890 - Dry Needling Dosage in the Treatment of Myofascial Neck Pain N/A
Completed NCT02051478 - Thoracic Manipulation and Mobilization for Neck Pain N/A
Completed NCT01938209 - A Comparison of Seated Thoracic Manipulation and Targeted Supine Thoracic Manipulation on Cervical Flexion Motion and Pain N/A
Completed NCT01205542 - Work Place Adjusted Intelligent Physical Exercise Reducing Musculoskeletal Pain in Shoulder and Neck (VIMS) - Shoulder Function N/A